Heart failure in patients with human immunodeficiency virus: a review of the literature

Coronary artery disease represents the leading cause of death for HIV patients treated with highly active antiretroviral treatment. Besides this, an extensive amount of data related to the risk of overt heart failure and consequently of atrial fibrillation and sudden cardiac death (SCD) in this population has been reported. It seems that persistent deregulation of immunity in HIV-infected patients is a common pathway related to both of these adverse clinical outcomes. Despite the fact that atrial fibrillation and heart failure are relatively common in HIV, few data are reported about screening, diagnosis, and potential treatment of these conditions.

[1]  M. Bansal.  Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies. The OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of , 2013 .

[2]  R. Hunter,et al.  Which are the most reliable predictors of recurrence of atrial fibrillation after transcatheter ablation?: a meta-analysis. , 2013, International journal of cardiology.

[3]  S. Piechnik,et al.  Comprehensive Cardiac Magnetic Resonance Imaging and Spectroscopy Reveal a High Burden of Myocardial Disease in HIV Patients , 2013, Circulation.

[4]  Jenny X. Sun,et al.  Risk assessment for incident heart failure in individuals with atrial fibrillation , 2013, European journal of heart failure.

[5]  G. Raff,et al.  Coronary computed tomographic angiography for detection of coronary artery disease in patients presenting to the emergency department with chest pain: a meta-analysis of randomized clinical trials. , 2013, European heart journal cardiovascular Imaging.

[6]  J. Esteve,et al.  Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of , 2013, Journal of the American College of Cardiology.

[7]  G. Marcus,et al.  Atrial fibrillation and atrial flutter in human immunodeficiency virus-infected persons: incidence, risk factors, and association with markers of HIV disease severity. , 2013, Journal of the American College of Cardiology.

[8]  P. Hsue,et al.  Human immunodeficiency virus-associated pulmonary arterial hypertension. , 2013, Clinics in chest medicine.

[9]  F. Gaita,et al.  Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. , 2013, European heart journal.

[10]  D. Costagliola,et al.  HIV and coronary heart disease: time for a better understanding. , 2013, Journal of the American College of Cardiology.

[11]  B. V. Van Tassell,et al.  Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis , 2013, BMJ.

[12]  D. Schadendorf,et al.  Prevalence of cardiovascular diseases in HIV-infected outpatients: results from a prospective, multicenter cohort study , 2013, Clinical Research in Cardiology.

[13]  N. Petrosillo,et al.  QTc interval prolongation in HIV-infected patients: a case–control study by 24-hour Holter ECG recording , 2012, BMC Cardiovascular Disorders.

[14]  E. Michelson,et al.  Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction. , 2012, American heart journal.

[15]  Successful left ventricular assist device bridge to transplantation in a patient with end-stage heart failure and human immunodeficiency virus. , 2012, Artificial organs.

[16]  J. Aberg.  Aging, inflammation, and HIV infection. , 2012, Topics in antiviral medicine.

[17]  M. Whooley,et al.  Six-minute walk test as a prognostic tool in stable coronary heart disease: data from the heart and soul study. , 2012, Archives of internal medicine.

[18]  M. Dąbrowska,et al.  HCV coinfection possibly promotes left ventricular dysfunction development: analysis of brain natriuretic peptide serum levels in HCV/HIV-coinfected and HIV-monoinfected patients , 2012, European journal of gastroenterology & hepatology.

[19]  K. Swedberg,et al.  Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. , 2012, Journal of the American College of Cardiology.

[20]  E. Vittinghoff,et al.  Sudden cardiac death in patients with human immunodeficiency virus infection. , 2012, Journal of the American College of Cardiology.

[21]  A. Di Iorio,et al.  Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan. , 2012, European review for medical and pharmacological sciences.

[22]  F. Gaita,et al.  Coronary artery disease Acute coronary syndromes in human immunodeficiency virus patients : a meta-analysis investigating adverse event rates and the role of antiretroviral therapy , 2012 .

[23]  K. Sliwa,et al.  Contribution of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic to de novo presentations of heart disease in the Heart of Soweto Study cohort. , 2012, European heart journal.

[24]  F. D’Ascenzo,et al.  Novel insights on HIV/AIDS and cardiac disease: shedding light on the HAART of Darkness. , 2012, European heart journal.

[25]  N. Ford,et al.  Preferred antiretroviral drugs for the next decade of scale up , 2012, Journal of the International AIDS Society.

[26]  Ziya Kaya,et al.  Autoantibodies in heart failure and cardiac dysfunction. , 2012, Circulation research.

[27]  M. Gomberg-Maitland,et al.  Treadmill testing improves survival prediction models in pulmonary arterial hypertension. , 2011, American heart journal.

[28]  L. Kuller,et al.  Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. , 2011, Archives of internal medicine.

[29]  O. Kirk,et al.  Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study , 2010, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[30]  S. Grandy,et al.  Reduction of Ventricular Sodium Current in a Mouse Model of HIV , 2010, Journal of cardiovascular electrophysiology.

[31]  R. Weber,et al.  Prevalence of comedications and effect of potential drug–drug interactions in the Swiss HIV Cohort Study , 2010, Antiviral therapy.

[32]  M. Humbert,et al.  HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era , 2010, AIDS.

[33]  S. Lai,et al.  HIV infection and abnormal regional ventricular function , 2009, The International Journal of Cardiovascular Imaging.

[34]  G. Bárbaro,et al.  Metabolic syndrome associated with HIV and highly active antiretroviral therapy , 2009, Current diabetes reports.

[35]  M. Bukrinsky,et al.  HIV infection and high density lipoprotein metabolism. , 2008, Atherosclerosis.

[36]  Arya M. Sharma,et al.  Relation of Epicardial Fat and Alanine Aminotransferase in Subjects With Increased Visceral Fat , 2008, Obesity.

[37]  S. Grandy,et al.  Cardiac repolarization is prolonged in CD4C/HIV transgenic mice. , 2007, Journal of molecular and cellular cardiology.

[38]  R. Erbel,et al.  MR characterization of cardiac abnormalities in HIV+ individuals with increased BNP levels. , 2007, European journal of medical research.

[39]  Arya M. Sharma,et al.  Relation of subepicardial adipose tissue to carotid intima-media thickness in patients with human immunodeficiency virus. , 2007, The American journal of cardiology.

[40]  Mardge H. Cohen,et al.  Association of Serum Lipid Levels With HIV Serostatus, Specific Antiretroviral Agents, and Treatment Regimens , 2007, Journal of acquired immune deficiency syndromes.

[41]  Arya M. Sharma,et al.  Epicardial adipose tissue is related to carotid intima-media thickness and visceral adiposity in HIV-infected patients with highly active antiretroviral therapy-associated metabolic syndrome. , 2007, Current HIV Research.

[42]  N. Dalton,et al.  Inducible Cardiac-Restricted Expression of Enteroviral Protease 2A Is Sufficient to Induce Dilated Cardiomyopathy , 2006, Circulation.

[43]  A. Yoshimura,et al.  Innate Defense Mechanism Against Virus Infection Within the Cardiac Myocyte Requiring gp130-STAT3 Signaling , 2006, Circulation.

[44]  B. Hesse,et al.  Right Ventricular Volume and Mass Determined by Cine Magnetic Resonance Imaging in HIV Patients with Possible Right Ventricular Dysfunction , 2006, Angiology.

[45]  Heidi M Crane,et al.  Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy , 2006, AIDS.

[46]  E. Schaefer,et al.  Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients. , 2006, Atherosclerosis.

[47]  M. Ntsekhe,et al.  Impact of Human Immunodeficiency Virus Infection on Cardiovascular Disease in Africa , 2005, Circulation.

[48]  C. Jericó,et al.  Hypertension in HIV-infected patients: prevalence and related factors. , 2005, American journal of hypertension.

[49]  S. Cole,et al.  Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study , 2005, AIDS.

[50]  P. Grammas,et al.  Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. , 2005, Biochemical and biophysical research communications.

[51]  M. Lauer,et al.  Exercise Testing in Asymptomatic Adults: A Statement for Professionals From the American Heart Association Council on Clinical Cardiology, Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention , 2005, Circulation.

[52]  J. Margolick,et al.  Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003 , 2005, AIDS.

[53]  Stephen R Cole,et al.  Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. , 2005, Archives of internal medicine.

[54]  N. Petrosillo,et al.  [Pulmonary hypertension and HIV: implementation of a Regional Registry]. , 2005, Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive.

[55]  J. Sztajzel,et al.  Utility of event loop recorders for the management of arrhythmias in young ambulatory patients. , 2004, International journal of cardiology.

[56]  Harlan M Krumholz,et al.  The association of 6-minute walk performance and outcomes in stable outpatients with heart failure. , 2004, Journal of cardiac failure.

[57]  R. Macko,et al.  Acquired Immunodeficiency Syndrome and the Risk of Stroke , 2003, Stroke.

[58]  S. Cole,et al.  Impact of HIV infection and HAART on serum lipids in men. , 2003, JAMA.

[59]  P. Volberding,et al.  The pavia consensus statement. , 2003, AIDS.

[60]  R. Greenblatt,et al.  Protease Inhibitor Use and the Incidence of Diabetes Mellitus in a Large Cohort of HIV‐Infected Women , 2003, Journal of acquired immune deficiency syndromes.

[61]  F. Fedele,et al.  Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue , 2001, Heart.

[62]  S. Lipshultz,et al.  Pathogenesis of HIV-associated cardiovascular complications. , 2001, The Lancet. Infectious diseases.

[63]  M. Humbert,et al.  Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. , 1998, The European respiratory journal.

[64]  S. Lipshultz,et al.  Cardiovascular manifestations of HIV infection. , 1996, Comprehensive therapy.

[65]  R. R. Meyer,et al.  Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine. , 1994, Circulation research.

[66]  S. Colan,et al.  Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine. , 1992, The New England journal of medicine.

[67]  H. Palevsky,et al.  Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. , 1992, The American review of respiratory disease.

[68]  R. Virmani,et al.  Congestive cardiomyopathy in association with the acquired immunodeficiency syndrome. , 1986, The New England journal of medicine.